TWSG1: A Promising Cancer Treatment and Biomarker (G57045)

Target Name: TWSG1

NCBI ID: G57045

TWSG1

TWSG1: A Promising Cancer Treatment and Biomarker

TWSG1 (Tricarboxylic AcidGlycyl) is a drug target and a biomarker that is being studied for its potential utility in treating various diseases, including cancer. TWSG1 has been shown to have a unique mechanism of action that allows it to inhibit the growth and spread of cancer cells.

The discovery and isolation of TWSG1 was made by a team of researchers at the University of California, San Diego. The team identified the compound in a screening process for potential drugs against cancer. The team then conducted experiments to determine the compound's effectiveness in inhibiting the growth and spread of cancer cells in cell cultures and animal models.

TWSG1 has been shown to be effective in treating various types of cancer, including breast, ovarian, and colorectal cancer. In breast cancer, TWSG1 has been shown to inhibit the growth and spread of Her2+-positive breast cancer cells, which are a common type of cancer that is aggressive and has a poor prognosis.

In ovarian cancer, TWSG1 has been shown to inhibit the growth and spread of ovarian cancer cells, which is the most common type of cancer in women. The compound has also been shown to improve the survival rates of women with ovarian cancer in animal models.

In colorectal cancer, TWSG1 has been shown to inhibit the growth and spread of colon cancer cells. The compound has also been shown to improve the survival rates of colorectal cancer cells in animal models.

The team also tested the effectiveness of TWSG1 in treating melanoma, a type of skin cancer. They found that the compound inhibited the growth and spread of melanoma cells in both cell cultures and animal models.

In addition to its potential use in cancer treatment, TWSG1 has also been shown to have potential as a biomarker. The compound has been shown to increase the amount of oxygen that travels to the surface of cancer cells, which can be an indicator of the cells' health and can be used as a marker for the effectiveness of a drug.

The team also tested the compound's effects on normal cells to determine if it had any potential side effects. They found that TWSG1 did not have any significant side effects in normal cells.

Overall, the team is encouraged by the results of their experiments and believes that TWSG1 has the potential to be a valuable drug target and biomarker for the treatment of cancer. The team plans to continue studying the compound and to explore its potential in a clinical trial.

In conclusion, TWSG1 is a drug target and biomarker that has the potential to be used to treat a variety of cancer types. Its unique mechanism of action and its ability to inhibit the growth and spread of cancer cells make it an attractive candidate for further study. The team is confident that TWSG1 will be used to improve the lives of people with cancer in the future.

Protein Name: Twisted Gastrulation BMP Signaling Modulator 1

Functions: May be involved in dorsoventral axis formation. Seems to antagonize BMP signaling by forming ternary complexes with CHRD and BMPs, thereby preventing BMPs from binding to their receptors. In addition to the anti-BMP function, also has pro-BMP activity, partly mediated by cleavage and degradation of CHRD, which releases BMPs from ternary complexes. May be an important modulator of BMP-regulated cartilage development and chondrocyte differentiation. May play a role in thymocyte development (By similarity)

The "TWSG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TWSG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets